JC124

JC124 is a specific NLRP3 inflammasome inhibitor. JC124 has anti-inflammatory and neuroprotective effects[1].

Signaling Pathways >> Immunology/Inflammation >> NOD-like Receptor (NLR)

Research Areas >> Inflammation/Immunology

Research Areas >> Neurological Disease

JC124 shows selective inhibition of NLRP3 inflammasome formation and activation of caspase-1, and reduction of IL-1β both in vitro[1].

JC124 (100 mg/kg; i.p.; 4 doses; 30 min post-injury, 6, 24, and 30 h after TBI) treatment significantly decreases the number of injury-induced degenerating neurons, inflammatory cell response in the injured brain, and cortical lesion volume. JC124 also significantly reduces protein expression levels of NLRP3, ASC, IL-1 beta, TNFα, iNOS, and caspase-1[1]. Animal Model: Adult male Sprague-Dawley rats (3-4-months-old) bearing traumatic brain injury (TBI)[1] Dosage: 100 mg/kg Administration: i.p.; 4 doses; 30 min post-injury, 6, 24, and 30 h after TBI Result: Significantly decreased the number of injury-induced degenerating neurons, inflammatory cell response in the injured brain, and cortical lesion volume.

[1]. Ram Kuwar, et al. A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury. J Neuroinflammation. 2019 Apr 11;16(1):81.